UroGen Pharma Ltd. — Director's Dealing 2021

May 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2021-05-17

Reporting Person: Smith Jason Drew (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-17	Common Stock	P	2500	$15.71	Acquired	2500	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.675
and 15.76, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.